Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
Manage pain and minimize opioids after hemorrhoidectomy
Significantly lower opioid use* 45% lower overall opioid consumption (P=0.0006)†
Significantly better pain control 30% lower cumulative pain scores (P<0.0001)†
Results from a phase 3, multicenter, randomized double-blind, placebo-controlled trial that evaluated the efficacy of 166 mg (20 mL) of EXPAREL in 186 patients undergoing 2- or 3-column excisional hemorrhoidectomy. Primary end point: cumulative pain score reflected in the AUC of numeric rating scale through 72 hours. Placebo was preservative-free saline for injection. Opioid rescue medication (up to 10 mg) of morphine administered intramuscularly was available to all patients.
AUC, area under the curve.
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
†Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.
For adults, a maximum dose of 266 mg (20 mL) is recommended, based on:
For pediatric patients aged 6 to less than 17 years, dosing is weight based: 4 mg/kg (up to a maximum of 266 mg)
See how your peers are using EXPAREL for optimal pain coverage
EXPAREL is a cost-effective option for postsurgical pain management both in the hospital and in outpatient settings
*Pain was measured using a visual analog scale (0 to 10).3
†The clinical benefit of the decrease in opioid consumption was not demonstrated in pivotal trials. Opioid utilization was measured using the World Health Organization’s defined daily dose (DDD), converting each opioid used into the respective DDD (intravenous fentanyl [1 DDD = 100 mcg], intravenous dilaudid [1 DDD = 2 mg], oral dilaudid [1 DDD = 4 mg], oral oxycodone [1 DDD = 20 mg], and hydrocodone [1 DDD = 10 mg]).3
†Costs were defined as the actual per-patient total costs for the entire inpatient episode.3
Multimodal approaches with or without ERAS protocols have demonstrated benefits in colorectal and general surgeries
Analysis comparing the efficacy of an ERAS protocol that included a TAP block with EXPAREL (n=42) compared with previously used standard of care.
ERAS, enhanced recovery after surgery; LOS, length of stay; NSAID; non-steroidal anti-inflammatory drug; PCA, patient-controlled analgesia; POD, postoperative day; TAP, transversus abdominis plane.
Retrospective trial comparing patients receiving local infiltration of EXPAREL (n=70) as part of an ERP with those being placed in an ERP (n=70).
*Opioid use was measured by the defined daily dose, with 1 unit equaling 100 mcg of intravenous fentanyl, 2 mg of intravenous hydromorphone HCl, 4 mg of oral hydromorphone HCl, 20 mg of oral oxycodone, or 10 mg of oral hydrocodone.
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
ERP, enhanced recovery pathway; ERAS, enhanced recovery after surgery; LOS, length of stay; PACU, postanesthesia care unit; TAP, transversus abdominis plane.
Retrospective, observational study comparing patients who received an ERAS protocol with EXPAREL (n=100) with a historical group prior to the introduction of the protocol (n=100).
ERAS, enhanced recovery after surgery; NSAID, nonsteroidal anti-inflammatory drugs; OSA, obstructive sleep apnea; PCA, patient-controlled anesthesia; POD, postoperative day.
Retrospective analysis comparing live kidney donors undergoing a laparoscopic nephrectomy under an ERAS protocol with EXPAREL (n=39) with live kidney donors under standard of care (n=40).
ERAS, enhanced recovery after surgery; LOS, length of stay.
Leading medical societies recommend opioid-minimizing pain management strategies to enhance recovery after colorectal and general surgeries procedures
ERAS
Colorectal Surgery 2018
Strong recommendation for the use of TAP blocks for minimally invasive colorectal surgery, noting that shorter acting local anesthetics have limited duration. Liposomal bupivacaine is included as an alternative to extend the duration.7
ASCRS and SAGES
Colorectal Surgery 2016
“Strong recommendation for the use of perisurgical multimodal, opioid-sparing, pain management plan, noting that lipsomal bupivicaine wound infiltration and transversus adbominis plan (TAP) blocks 'have shown promising results in patients undergoing open and laparoscopic colorectal surgery.’”8
ASCRS, American Society of Colon and Rectal Surgeons; ERAS, enhanced recovery after surgery; SAGES, Society of American Gastrointestinal Endoscopic Surgeons.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.